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Background. Epidural opioids have excellent analgesic properties, but their side-effects limit
their use in patient-controlled epidural analgesia. This study was designed to evaluate the
effect of epidural naloxone on the side-effects of sufentanil, focusing on postoperative nausea
and vomiting (PONV) in patients undergoing total knee replacement (TKR).
Methods. After obtaining Institutional Review Board approval and informed consent, 50
patients undergoing unilateral TKR were randomly assigned to receive either sufentanil in ropi-
vacaine alone (Group C, n¼25) or the same solution with naloxone (Group N, n¼25) for
their postoperative epidural analgesia. Episodes of PONV and five-point-scaled nausea scores
were evaluated at 6, 12, and 24 h after epidural analgesia was started. Visual analogue scale
(VAS) score for pain and the incidence of sedation, pruritus, hypotension, and respiratory
depression were also evaluated at each of three time points.
Results. The nausea score in Group N was significantly lower than that in Group C. The VAS
pain score at rest and on movement were significantly lower in Group N than in Group C at
24 h. Other opioid-induced side-effects were not significantly different.
Conclusions. Epidural naloxone was effective in reducing PONV induced by epidural sufenta-
nil and additionally enhanced the analgesic effect. Therefore, concomitant infusion of a small
dose of epidural naloxone should be considered to reduce PONV, especially in patients at
greater risk for PONV.
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Total knee replacement (TKR) is associated with severe
postoperative pain and adequate pain relief is essential in
the postoperative period.1 2 An epidural infusion of a local
anaesthetic–narcotic mixture is a common modality for
pain relief after TKR,3 and epidural morphine is widely
used.4 However, it has been associated with respiratory
depression, postoperative pruritus, and postoperative nausea
and vomiting (PONV). The reported incidences of post-
operative pruritus and PONV vary from 8.5% to 90%, and
from 34% to 70%, respectively, in patients receiving
epidural morphine.5 – 8 Sufentanil, a highly lipophilic
opioid, is used instead of morphine because epidural
sufentanil may produce analgesia primarily by a spinal
mechanism when combined with local anaesthetics.9
Epidural sufentanil, when compared with morphine, has
been associated with a lower incidence of delayed respirat-
ory depression.10 However, the incidence of PONV has
remained high in patients administered epidural sufenta-
nil.11 – 13
Previous studies reported that small doses of the opioid
antagonist naloxone administered i.v. and epidurally allow
maintenance of analgesia while reducing morphine-related
side-effects such as pruritus, nausea, and intestinal hypo-
motility.14 – 16 This study was designed to evaluate the
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effect of epidural naloxone on the side-effects of sufenta-
nil, focusing on PONV in patients undergoing TKR.
Methods
After obtaining approval of the Institutional Review
Board and written informed consent, 50 adult patients
with ASA physical status I–II undergoing primary, unilat-
eral TKR were included. Patients were excluded from the
study if they had contraindications to neuraxial anaesthe-
sia, allergy to study drugs, chronic opioid use, significant
myocardial, renal, or hepatic impairment, or nausea and
vomiting during the operation. Subjects were then allo-
cated to one of the two treatment groups in the post-
anaesthesia care unit and received either sufentanil in ropi-
vacaine (Group C, n¼25) or sufentanil in ropivacaine with
naloxone (Group N, n¼25) for their postoperative epidural
analgesia. Group assignment was randomized using a
sealed envelope system. Both patients and anaesthesia pro-
viders were blinded with respect to study group allocation
throughout the study period. An independent researcher
prepared the study solutions. The study solution of Group
C consisted of ropivacaine 0.2% and sufentanil
1.0 mg ml21 and the study solution of Group N consisted
of ropivacaine 0.2% and sufentanil 1.0 mg ml21 with
preservative-free naloxone. The amount of naloxone,
which was based on patient’s body weight, in 1 ml of the
study solution of Group N was 0.0333 mg kg21. The basal
rate of the patient-controlled analgesia (PCA) device was
set at 6 ml h21 and the bolus dose was set 0.5 ml with a
15 min lockout period, which made the maximum infusion
rate to be 8 ml h21. Therefore, the infusion range of nalox-
one was 0.20–0.27 mg kg21 h21. Before surgery, patients
were instructed on the use of the PCA device and the
visual analogue scale (VAS) score for pain assessment.
Patients were placed in a left lateral decubitus position
for a combined spinal-epidural procedure. After local
anaesthesia of the skin at the L3–4 or L4–5 interspace, an
18-gauge Tuohy needle (Portex, NH, USA) was introduced
via a midline approach into the epidural space using a loss
of resistance technique. A 27-gauge Whitacre tip spinal
needle was then placed through the Tuohy needle, and
subarachnoid placement was confirmed by the free flow of
cerebrospinal fluid (CSF). All patients received isobaric
tetracaine 0.5%, 2 ml (Pantocainsterile, Daihan pharm.,
Seoul, Korea) with 1:1000 epinephrine 0.1 ml. The spinal
needle was removed and a 20-gauge, closed end, multiport
catheter (Portex, NH, USA) was inserted 4–5 cm cephalad
within the epidural space, and the patient was placed in a
supine position. Electrocardiogram and arterial oxygen sat-
uration were monitored continuously and blood pressure
was recorded non-invasively every 5 min until the end of
the surgical procedure, and then every 10 min until recov-
ery. If the arterial blood pressure of the patient decreased
by more than 20% from baseline, then 300–500 ml of
colloids and incremental boluses of i.v. ephedrine (4–
6 mg) were used. Scores for pain, sensory block level,
intensity of motor block, nausea, sedation, pruritus, respir-
atory depression, and hypotension were recorded at 20 min
after the spinal anaesthesia. Pain was scored on a 100 mm
VAS (0¼no pain, 100¼the worst pain imagined). The
sensory block level was assessed at the maximal level of
cold sensation at the midclavicular line using an alcohol
swab bilaterally. The intensity of motor block was evalu-
ated with the Bromage scale (1¼no motor block, 2¼knee
blocked and mobility of ankle preserved, 3¼mobility of
ankle difficult, and 4¼knee and ankle blocked). A venti-
latory frequency8 bpm was defined as respiratory
depression, and a decrease in mean arterial blood pressure
more than 20% from the basal value was defined as
hypotension.
When patients arrived at the post-anaesthesia care unit,
a physician blinded to the treatment group assessed initial
sensory block level, which was assessed at the maximal
level of cold sensation at the midclavicular line using an
alcohol swab bilaterally. The sensory block level was then
checked at 10 min intervals until regression of the
sensory level below T10. When regression of the sensory
level was below the T10 dermatome, epidural analgesia
was started using the PCA technique with an electronic
infusion pump (WalkMedw PCA, McKinley, CO, USA)
containing the study solution by a physician blinded to the
treatment group. The infusion pump setting included a
6 ml h21 continuous infusion and a 0.5 ml bolus dose with
a 15 min lockout period for 24 h after operation. Patients
with a VAS pain score higher than 50 were given meperi-
dine 25 mg i.m. as rescue analgesia. Patients with a
nausea score higher than 3 were given ondansetron
4–6 mg i.v. Each patient was interviewed at 6, 12, and
24 h after the start of epidural PCA administration. At
these time points, episodes of PONV and nausea score
were recorded. Nausea was defined as the subjective sen-
sation of a desire to vomit without any expulsive muscular
movements. Vomiting was defined as expulsive efforts fol-
lowed by elimination of gastric content. The nausea score
was categorized as 1¼no nausea, 2¼mild nausea, treat-
ment is not necessary, 3¼moderate nausea, treatment may
be desirable, but patient can tolerate it, 4¼severe nausea
and treatment is necessary, 5¼intractable nausea, patient
complains despite treatment.17 Pain intensity was assessed
at rest and on movement using the VAS. In addition, upper
level of cold sensation, intensity of motor block, somno-
lence, pruritus, and respiratory depression were recorded.
Urinary retention could not be assessed at 6 or 12 h
because all patients had an indwelling urinary catheter at
12 h after operation.
Sample size was based on the power analysis from a
similar epidural PCA study,17 which adopted this 0.7
nausea score difference, an a risk of 0.05 and a b risk of
0.2 (SigmaStat 3.1, Systat Software, Inc., CA, USA).
Statistical analysis was performed using the Statistical
Effect of epidural naloxone on PONV
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Package for Social Sciences software (SPSS 12.0 for
windows, SPSS Inc., IL, USA). Results are expressed as
mean (SD), mean (range), median (inter-quartile range), or
a number of patients. x2 tests, independent t-tests, and
Mann–Whitney U-test were used to compare variables
between the groups where appropriate. The VAS scores
between groups were analysed with repeated measures of
analysis of variance (ANOVA) followed by Bonferroni-
corrected post hoc analysis. A P-value of less than 0.05
was considered statistically significant.
Results
Fifty patients completed the study protocol. Patient charac-
teristics excluding body weight were comparable between
the two groups. The duration of surgery and the history of
PONV and motion sickness were comparable between the
two groups. The maximal levels of sensory block at
20 min after spinal anaesthesia were also similar (Table 1).
The VAS pain scores at rest and on movement were sig-
nificantly lower in Group N than in Group C at 24 h
(P¼0.001 and 0.013, respectively) (Figs 1 and 2). There
were no differences in total infused volume of analgesic
regimen and supplemental analgesic use between the two
groups (Table 2).
Nausea scores were significantly lower in Group N than
in Group C at 6 and 12 h after PCA was started (P,0.05)
(Table 3). The use of anti-emetic agents was significantly
lower in Group N than in Group C at 6, 12, and 24 h (P,
0.05) (Table 3).
There were no significant differences in pruritus or
sedation between the two groups (Table 4).
No patients in either group had respiratory depression
and hypotension.
No patients in either group had urinary retention at 24 h.
Discussion
The results of this study indicate that the concomitant epi-
dural infusion of sufentanil and naloxone for postoperative
Fig 1 Mean VAS pain scores at rest. Mean VAS pain scores at 6, 12, and
24 h after the infusion of PCA regimens were lower in Group N, but only
the difference in the VAS pain score at 24 h was statistically significant.
Values are mean (SD). *Significantly different compared with Group C
(P¼0.001).
Fig 2 Mean VAS pain scores on movement. Mean VAS pain scores on
movement at 6, 12, and 24 h after the infusion of PCA regimens were
lower in Group N, but only the difference in the VAS pain score at 24 h
was statistically significant. Values are mean (SD). *Significantly different
compared with Group C (P¼0.013).
Table 2 Total infused volume of analgesic regimen (TIVAR) during 0–6, 6–
12, 12–24 h and patients requiring i.m. meperidine 25 mg at 6, 12, and 24 h
after the infusion of PCA regimens. Values of TIVAR are means (SD) and
those for i.m. meperidine are the number of patients (%). PCA,
patient-controlled analgesia
Group C (n525) Group N (n525)
TIVAR (ml)
0–6 h 37.9 (3.7) 37.7 (4.5)
6–12 h 40.1 (9.6) 39.7 (5.8)
12–24 h 74.3 (4.8) 73.4 (5.5)
I.M. meperidine
6 h 5 (20) 3 (12)
12 h 7 (28) 3 (12)
24 h 13 (52) 9 (36)
Table 1 Patients’ characteristic, past history, and duration of surgery. Weight,
height, BMI, and duration of surgery values are given as mean (SD), age as
mean (range), history of PONV and motion sickness as the number of patients
(%) and maximal sensory block as median (inter-quartile range). BMI, body
mass index; PONV, postoperative nausea and vomiting. *Significantly
different compared with Group C (P,0.05)
Group C (n525) Group N (n525)
Sex (M/F) 3/22 4/21
Age (yr) 66.9 (53–74) 66.3 (55–75)
Height (cm) 152.6 (6.1) 154.6 (6.9)
Weight (kg) 61.2 (8.7) 66.3 (9.1)*
BMI (kg m22) 26.3 (3.4) 27.8 (4.0)
History of PONV 5 (20) 6 (24)
History of motion sickness 4 (16) 2 (8)
Maximal sensory block T6 (T6–T8) T6 (T6–T8)
Duration of surgery (min) 84.9 (9.1) 86.2 (17.1)
Kim et al.
272
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on June 2, 2014
http://bja.oxfordjournals.org/
D
ow
nloaded from
 
analgesia not only reduces the incidence and severity of
PONV but also enhances the analgesic effect of sufentanil.
Although overall VAS pain scores were lower in Group N,
only the difference in the VAS pain score at 24 h was stat-
istically significant.
Epidural administration of opioids combined with local
anaesthetic is a popular method in perioperative analgesia
because of its synergistic effect. However, opioid-induced
side-effects such as nausea and vomiting, pruritus, respir-
atory depression, and urinary retention limit the use of
opioids in postoperative pain control because these side-
effects can be more distressing and debilitating than the
pain itself. In particular, PONV is a major concern in opioid
analgesia because patients rated PONV as the most unde-
sirable side-effect and indicated that avoidance of PONV
was of a higher priority than avoidance of postoperative
pain.18 The most commonly identified risk factors for
PONV include female gender, non-smoking status, history
of PONV or motion sickness, extended duration of anaes-
thesia, postoperative opioid use, and age.19 20 Roberts and
colleagues21 reported that both postoperative opioid use
and female gender significantly influenced PONV,
whereas opioid use, in particular, had a dose-dependent
relationship with PONV. In studies that included both
male and female patients receiving epidural analgesia, the
overall mean incidence of nausea was 18.8% (14.0–
24.8%), and vomiting occurred in 16.2% (12.5–20.7%).
The incidence of nausea and vomiting was higher in
studies that included only female patients, 39.1% (26.3–
53.7%) and 30.2% (24.3–36.9%), respectively.22
There have been many trials aimed at reducing the side-
effects of neuraxial opioids. Some of these studies investi-
gated the use of lipophilic opioids instead of hydrophilic
opioids such as morphine. Sufentanil, a lipophilic opioid,
offers some unique advantages due to its greater lipophili-
city and m-receptor-binding capacity. Whether epidurally
administered sufentanil acts spinally or supraspinally via
systemic absorption remains controversial. However, a
series of studies of epidural sufentanil infusion after thora-
cotomy demonstrated that the concentration of epidural
sufentanil was higher in CSF than in plasma and that
sufentanil was highly localized within the CSF to the level
of administration after both single bolus administration
and infusion.23 24 Joris and colleagues9 also proved that in
combination with epidural local anaesthetic, sufentanil
requirements were less epidurally than i.v., suggesting that
epidural sufentanil produces analgesia primarily by a
spinal mechanism when combined with local anaesthetic.
Studies exploring the side-effects of epidural sufentanil
have not shown consistent results. However, in most
studies using epidural sufentanil, the incidence of PONV
was higher than that of other side-effects.11 – 13 23 In this
study, no patients receiving epidural sufentanil in ropiva-
caine without naloxone had serious side-effects related to
neuraxial opioids other than PONV. The second most
common opioid-related side-effect in these patients was
pruritus (8–16%) but only one patient (4%) required
treatment.
Another avenue in decreasing the side-effects of
epidural opioids is the concurrent use of low-dose nalox-
one i.v. or epidurally.14 – 16 25 I.V. infusion of naloxone at
0.25 mg kg21 h21 has been effective in reducing and
reversing morphine-related side-effects without affecting
analgesia or even paradoxically enhancing morphine’s
analgesic potency.14 25 However, since i.v. infusion of nalo-
xone requires another infusion device separate from the
epidural device in patients receiving epidural analgesia
for postoperative pain control, naloxone was mixed
with epidural morphine in local anaesthetics in two pre-
vious human studies.15 16 This continuous naloxone infu-
sion reduced pruritus, nausea, and intestinal hypomotility
without affecting analgesia. In animal studies, the safety
of neuraxial naloxone and its neuroprotective effect has
been proved.26 27 Cole and colleagues26 reported that with
a 1.0 mg kg21 intrathecal dose of naloxone, there was no
histological evidence of spinal cord toxicity or behavioural
and physiological perturbations in the rat. Furthermore,
they have demonstrated a protective effect of intrathecal
naloxone against spinal cord injury.
Table 3 Incidence of PONV, nausea score, and patients requiring anti-emetics
at 6, 12, and 24 h after the infusion of PCA regimens. Values are number of
patients (%). PCA, patient-controlled analgesia; PONV, postoperative nausea
and vomiting. aNausea score was categorized as 1¼no nausea, 2¼mild
nausea, treatment is not necessary, 3¼moderate nausea, treatment may be
desirable, but patient can tolerate it, 4¼severe nausea and treatment is
necessary, 5¼intractable nausea, patient complains despite treatment.
*Significantly different compared with Group C (P,0.05)
Group C (n525) Group N (n525)
No. of patients having episodes
of PONV (%)
6 h 13 (52) 7 (28)
12 h 10 (40) 5 (20)
24 h 10 (40) 6 (24)
Nausea scorea (1/2/3/4/5)
6 h 12/4/4/5/0 18/5/2/0/0*
12 h 15/1/4/5/0 20/4/1/0/0*
24 h 15/4/5/1/0 19/4/2/0/0
Anti-emetic use
6 h 13 (52) 4 (16)*
12 h 7 (28) 1 (4)*
24 h 7 (28) 1 (4)*
Table 4 Incidence of pruritus and sedation at 6, 12, and 24 h after the
infusion of PCA regimens. Values are number of patients (%). PCA,
patient-controlled analgesia
Group C Group N
Pruritus
6 h 2 (8) 0
12 h 1 (4) 0
24 h 4 (16) 0
Sedation
6 h 1 (4) 3 (12)
12 h 2 (8) 2 (8)
24 h 1 (4) 1 (4)
Effect of epidural naloxone on PONV
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It is better to infuse naloxone continuously because it
has a half-life of 55 min and therefore intermittent admin-
istration will result in the fluctuation of naloxone concen-
tration.28 Other studies on naloxone used either a
continuous or intermittent technique.15 16 28 In addition to
continuous infusion, an intermittent bolus dose of nalox-
one was also given at the same time as the opioid solution
was triggered by the PCA pump because naloxone was
mixed with the opioid solution in this study. This method
of administration may have further reduced side-effects
because the ratio of the blood concentrations of sufentanil
and naloxone was maintained constant throughout the
study period.
The concentration of naloxone used in this study
was based on that used in other studies, which ranged from
0.167 mg kg21 h21 to 0.412 mg kg21 h21 in patients receiv-
ing epidural morphine.15–17 Among patients receiving nalox-
one, the mean (SD) dosage received over 24 h was 0.21
(0.01) mg kg21 h21. The mean (SD) dosage of naloxone
received over the first 6 h was 0.21 (0.03) mg kg21 h21, over
the second 6 h 0.22 (0.03) mg kg21 h21, and for the last
12 h 0.20 (0.01) mg kg21 h21.
In this study, no patients receiving epidural sufentanil
in ropivacaine had any serious side-effects except
PONV, regardless of whether they received naloxone co-
administration. PONV was markedly reduced in patients
receiving a concomitant infusion of naloxone. Further-
more, both nausea scores and anti-emetic use were signifi-
cantly lower in these patients. Considering that the
majority of patients receiving epidural naloxone were
female, the incidence of PONV was lower than that seen
in other studies.22 A low dose of epidural naloxone not
only reduced PONV but also improved the VAS pain score
at 24 h in Group N. The potential mechanisms for these
effects of low doses of naloxone include: (1) low-dose
naloxone may enhance release of endogenous opioid pep-
tides by blocking presynaptic autoinhibition of enkephalin
release29 and (2) low-dose naloxone directly and competi-
tively antagonizes the Gs protein-coupled excitatory opioid
receptors that are responsible for the hyperalgesia
occasionally reported with opioid administration without
attenuating inhibitory Gi/Go-coupled opioid receptors
mediating analgesia.30
There are several limitations to this study. First, we used
i.m. meperidine as rescue analgesia because the ortho-
paedic surgeon was unwilling to use a non-steroidal anti-
inflammatory drug due to its negative effect on bone
healing. Although there were no differences in the inci-
dence and severity of PONV between patients with and
without meperidine in this study, the use of another opioid
may have influenced the incidence of PONV. Secondly,
the naloxone dose used was weight-based but that of
sufentanil and ropivacaine was not. This was in line with
other studies on opioids and local anaesthetics, in which
the continuous infusion rate and bolus dose in adults were
not weight-based. On the other hand, studies on epidural
naloxone were all weight-based doses, and since there
was no other reference dose, a weight-based dose was
used.15 – 17
In conclusion, epidural naloxone was effective in redu-
cing PONV induced by epidural sufentanil and addition-
ally enhances the analgesic effect. Therefore, concomitant
infusion of a small dose of naloxone should be considered
to reduce PONV, especially in patients at greater risk for
PONV.
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